OBJECTIVES: Psoriatic arthritis (PsA) treatment may involve use of biologic injections/infusions. Apremilast was recently approved for treatment of adults with active PsA. Oral apremilast is priced significantly lower than biologics. Published comparative healthcare cost data are lacking for PsA patients receiving apremilast vs. biologics in a real-world care setting. We compared healthcare costs among PsA patients initiating apremilast or a biologic from the US managed care perspective. METHODS: Adults with ≥2 diagnosis codes for PsA (ICD-9:696.0) were selected from the 2014-2105 MarketScan Commercial and Medicare Supplemental database. The first prescription date was defined as the index date; patients had to be continuously enrolled for ≥6 months pre-index and ≥3 months post-index. To ensure new patient starts, biologic users had to be treatment-naïve to index medication in the pre-index period, although prior use of another biologic was not reason for exclusion. Healthcare costs (2014 US$) were defined as the sum of pharmacy+medical service costs (e.g., inpatient, outpatient [including intravenous infusions], emergency, and all other services [laboratory, radiology, other ancillary services]). Results, expressed as cost/patient/month, were reported separately for disease-specific PsA costs. RESULTS: